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Receptor activity-modifying proteins (RAMPs) are single transmembrane spanning 
proteins which serve as molecular chaperones and allosteric modulators of G protein coupled 
receptors (GPCRs) and their signaling pathways. Although RAMPs have been previously studied 
in the context of their effects on Family B GPCRs, the coevolution of RAMPs with many GPCR 
families suggests an expanded repertoire of potential interactions. Using BRET-based and cell 
surface expression approaches, we comprehensively screen for RAMP interactions within the 
chemokine receptor family and identify robust interactions between RAMPs and nearly all 
chemokine receptors.  Most notably, we identify robust RAMP interaction with atypical chemokine 
receptors (ACKRs), which function to establish chemotactic gradients for directed cell migration. 
Specifically, RAMP3 association with atypical chemokine receptor 3 (ACKR3) diminishes 
adrenomedullin (AM) ligand availability without changing G protein coupling. Instead, RAMP3 is 
required for the rapid recycling of ACKR3 to the plasma membrane through Rab4-positive 
vesicles following either AM or SDF-1/CXCL12 binding, thereby enabling formation of dynamic 
spatiotemporal chemotactic gradients. Consequently, genetic deletion of either ACKR3 or RAMP3 
in mice abolishes directed cell migration of retinal angiogenesis. Thus, RAMP association with 
chemokine receptor family members represents a novel molecular interaction to control receptor 
signaling and trafficking properties. 
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Significance Statement:  G protein coupled-receptors (GPCRs) exist within multi-protein 
complexes on the surface of cells in order to respond to a wide variety of extracellular stimuli such 
as neurotransmitters, migratory cues, hormones, light and odors. In this study, we discover and 
characterize an expanded repertoire of GPCRs that interact with receptor activity modifying 
proteins (RAMPs)—a class of proteins that can modulate the type and consequences of 




GPCRs is essential for enabling these receptors to bind and degrade extracellular migratory cues 
and thereby establish gradients for directed cellular migration. In the absence of these critical 





RAMPs are a family of single-pass transmembrane proteins with 3 mammalian members: 
RAMP1, RAMP2 and RAMP3, each encoded by a distinct and corresponding gene (1-3).  The 
RAMPs were first identified by virtue of their requirement for promoting the forward translocation 
of calcitonin receptor-like receptor (CLR) from the cytoplasm to the plasma membrane (3).  
Moreover, their association with this receptor imparts ligand binding specificity, such that a 
RAMP1-CLR oligomer preferentially binds the neuropeptide, calcitonin gene related peptide 
(CGRP), whilst the RAMP2-CLR or RAMP3-CLR oligomers display higher affinity for a related 
vasodilatory peptide, adrenomedullin (AM).  Recent cryo-EM resolution of the molecular 
interaction between RAMP1 and calcitonin receptor-like receptor (CLR) exemplifies how RAMPs 
impart ligand binding specificity (4), which has been exploited in the design of the first FDA-
approved antibody-based therapy against a GPCR for the treatment of migraine (5).  Subsequent 
studies have further defined critical roles for RAMPs to impart biased downstream signaling and 
intracellular trafficking dynamics to numerous G protein-coupled receptors (GPCRs).  However, 
these pleiotropic effects of RAMPs have mostly been studied in the context of a few receptors in 
the Family B/Secretin family, including calcitonin receptor (CTR), secretin receptor, glucagon (6, 
7), CRF1 (8, 9) and VPAC1/2 (8) and the Family A receptors, CaSR,(10) and GPR30/GPER1(11).  
The strong co-evolution of RAMPs with most GPCR families suggests that they may have 
expanded interacting partners (12, 13).  
The chemokine receptor subfamily is comprised of 24 different GPCRs that each bind a 
diverse array of chemokine and peptide ligands, leading to a wide variety of signaling events and 
physiological functions, ranging from innate immunity, developmental chemotaxis, HIV infection 
to cancer metastasis (14-16).  The redundancy of ligands binding to multiple chemokine receptors 
underscores the importance, and also the complexity, of chemokine signaling.  As one example, 




concerted, spatiotemporal functions of both typical signaling chemokine receptors with atypical 
chemokine receptors (ACKRs), sometimes referred to as “decoy” receptors (17). Unlike typical 
chemokine receptors which elicit a downstream signaling pathway in response to ligand, ACKRs 
do not signal through G proteins but rather bind and degrade ligands rapidly from the extracellular 
milieu.  Considering this high level of complexity in ligand binding and signaling, we hypothesized 
that RAMPs may interact with chemokine receptors to modulate their complex signaling, 
trafficking, and physiological properties.  Here, we developed a multimodal screening platform 
which identified robust interactions between RAMPs and the family of chemokine receptors.  We 
further find that RAMPs play essential roles in determining the internalization, trafficking and 
recycling of ACKR3, ultimately influencing guided angiogenesis in the postnatal retina. 
Results 
Identification of chemokine receptor: RAMP interactions using BRET and FACS 
We established a bioluminescence resonance energy transfer (BRET)-based screening 
platform to identify RAMP-GPCR protein interactions by transiently co-expressing a constant 
amount of GPCR-rLuc protein with increasing amounts of RAMP-YFP protein in HEK293T cells.  
The canonical RAMP-interacting receptor, CLR, was used as a positive control and the non-
interacting beta-2 adrenergic receptor (β2ADR) served as a negative control in order to empirically 
establish a systematic and multi-variate process for identifying and scoring RAMP:GPCR 
interactions.  To evaluate each interaction, the first major discriminator applied was a threshold 
of Bmax > 0.100 (Fig. 1 and SI Appendix, Table S1).  All potential interactions failing to reach this 
minimum signal level were deemed negative, as indicated by red shading.  Next, we applied a 
best-fit comparison for linearity versus hyperbolic curve fitting for all curves with a Bmax > 0.100. 
Interactions with a linearity R2 greater than the hyperbolic R2 were considered poor, indicated by 
yellow shading.  Finally, the remaining curves which satisfied the hyperbolic curve fit test were 




considered good interactions and colored blue, whilst curves with BRET50 < 10 were considered 
the strongest possible candidates and shaded green. All chemokine receptors exhibited 
interactions with at least one RAMP. RAMP3 interactions were the most frequent and strongest 
(24/24 receptors), followed by RAMP2 (20/24) and RAMP1 (15/24) (Fig. 1).  
Flow cytometry was performed as an orthogonal assay to verify if BRET-based protein- 
protein interactions translated to effects on RAMP surface expression upon cotransfection with 
each receptor (SI Appendix, Fig. S1A). In the absence of a GPCR, FLAG- and HA-RAMP1 and 
RAMP2 displayed minimal plasma membrane expression, indicative of endogenous intracellular 
localization. Both FLAG- and HA-RAMP3 exhibited endogenous plasma membrane expression, 
an effect also observed in previous studies (18). Importantly, RAMP3 plasma membrane 
expression could be further enhanced by coexpression with CLR or CTR. CCR5, CXCR2, 
CX3CR1 and CMKLR1 exhibited highly significant RAMP interactions in both BRET-based and 
cell surface expression assays. Interestingly, we noticed that three of the members of the 
subfamily of confirmed atypical chemokine receptors (ACKR1-3, but not ACKR4) interacted 
robustly with RAMP3 and unlike RAMP1/2, reduced RAMP3 cell surface expression compared to 
RAMP3 expressed alone. To confirm that the observed effects on RAMP cell surface expression 
were not due to overexpression, FLAG-RAMPs were titrated with a fixed concentration of 
receptor. We observed a saturable level of cell surface expression above vector alone for FLAG-
RAMP1 with CCR5 and FLAG-RAMP2 with CXCR2, with the plateau corresponding to a 1:1 
RAMP:receptor ratio (SI Appendix, Fig. S1B). For FLAG-RAMP3, which is able to traffic to the 
plasma membrane alone, ACKR3 restricted its cell surface expression in a saturable manner. 
ACKR3 has been reported to more broadly localize to early endosomes prior to ligand stimulation 
(19). Therefore, a possible explanation for the reduced FLAG-RAMP3 plasma membrane 
localisation upon coexpression with ACKR3, is that the ACKR3: RAMP3 complex resides largely 




other GPCRs that reduce FLAG-RAMP3 plasma membrane expression. Interestingly, but not 
unexpectedly, the results from the BRET and FACS experiments reveal some differences in 
specific RAMP:GPCR interactions. The BRET assay provides a measure of total protein:protein 
interactions regardless of cellular location, whereas FACS is, one of a number of techniques  that 
measure the extent to which GPCRs alter RAMP expression at the cell surface. Thus, a 
comparative integration of results for these two methodologies provides the most informed 
interpretation for the biological functions of these putative RAMP:GPCR interactions. 
ACKR3 interacts with RAMP2/3 without affecting G protein or β-Arrestin coupling 
 We were particularly intrigued by the putative ACKR3:RAMP interaction because, using 
genetic mouse models, we previously showed that the developmental phenotypes of precocious 
cardiomyocyte and lymphatic hyperplasia in Ackr3-/- mice are attributable to gain-of-function in 
AM ligand (20), which elicits its signaling through the canonical RAMP-interacting receptor 
heterodimers, CLR:RAMP2 and CLR:RAMP3.  Therefore, we hypothesized that ACKR3 may also 
utilize RAMPs to modulate its ligand scavenging activities. To address this, we further validated 
the ACKR3:RAMP3 protein interaction by observing the co-localization of Myc-ACKR3 and HA-
RAMP3 at the plasma membrane of non-permeabilized HEK293T cells by confocal microscopy 
(Fig. 2A) and within the cytoplasm by proximity ligation assay (Fig. 2B), to an extent similar to 
that observed for the CLR:RAMP positive controls.  Consistent with the established scavenging 
properties of ACKRs, we used the BRET-based biosensor EPAC (21) to confirm that neither 
RAMP 1, 2, or 3 could induce activation of Gαs (SI Appendix, Fig. S2A) nor Gαi/o (SI Appendix, 
Fig. S2B) in response to logarithmic dosage of AM or SDF-1/CXCL12 ligands.  Furthermore, we 
did not detect any effects of RAMPs on the AM- or SDF-1/CXCL12-induced recruitment of β-
arrestin-1-YFP or β-arrestin-2-YFP to ACKR3-rLuc, as evidenced by non-linear regression best-
fit curves of BRET activation (SI Appendix, Fig. S2C,D). Both AM and SDF-1/CXCL12 ligand 




showed more efficacy at lower doses than AM (SI Appendix, Fig. S2C,D). Collectively, these 
data establish RAMPs as interacting partners of ACKR3, but these interactions do not influence 
the downstream G protein or β-arrestin responses of ACKR3 to either AM or SDF-1/CXCL12 
ligands. 
ACKR3: RAMP3 co-expression scavenges and attenuates AM signaling 
 We next established cell based cAMP-EPAC reporter assays to distinguish the cell 
intrinsic and cell autonomous functions of ACKR3 on AM ligand scavenging via activation of the 
CLR:RAMP3 receptor heterodimer. For example, HEK293T cells transfected with CLR, RAMP3, 
NSF (N-ethylmaleimide sensitive factor), and the EPAC reporter responded in a dose-dependent 
manner to AM stimulation (EC50=1.6 nM ± logEC50=0.11, purple circles (Fig. 3A)), and this 
signaling could be significantly attenuated with a large effect at high AM concentrations, evident 
by the development of a biphasic dose-response curve fit, by the co-transfection of ACKR3 
(EC50_1= 1 nM ± logEC50_1= 0.20 and EC50_2= 3.1 µM ± logEC50_2= 0.46, orange squares 
(Fig. 3A)) This was consistent with our previous results showing reduced pERK activation by AM 
in the presence of ACKR3 (20). Because we found that RAMPs did not induce ACKR3 mediated 
cAMP production in response to AM (SI Appendix, Fig. S2A,B), we reasoned that the reduced 
potency of AM at the CLR:RAMP3 receptor is caused by reduced bioavailability of AM ligand in 
the presence of the ACKR3 scavenging receptor. To confirm this, and to provide a model for the 
cell autonomous scavenging effects of ACKR3 on AM ligand, we employed a co-culture system 
in which reporter cells expressing CLR:RAMP3:EPAC were co-cultured with cells expressing 
either ACKR3:RAMP3:NSF or glucagon like peptide 2 receptor (GLP2R), as a non-scavenging 
control cell (Fig. 3B). Upon stimulation with AM, the CLR:RAMP3:EPAC reporter cells co-cultured 
with the non-scavenging GLP2R-expressing cells stimulated maximal cAMP production with a 
potency of 0.52 nM ± logEC50=0.05 (black circles). In contrast, when the CLR:RAMP3:EPAC 




loss in potency to 1.3 nM ± logEC50=0.08, as demonstrated by the rightward shift in the dose-
response curve (red squares). These data demonstrate the ability of ACKR3:RAMP3 to scavenge 
AM ligand both in cell intrinsic and cell autonomous settings, thereby attenuating AM signaling 
and further validating our previous studies using genetic mouse models. 
ACKR3 rapid recycling and lysosomal trafficking is dependent upon RAMP3 and NSF 
 An inherent characteristic for establishing and maintaining chemotactic gradients for 
guided cell migration within discrete spatiotemporal boundaries, is the rapid and dynamic 
depletion of extracellular ligands from the non-migrating region (22).  Elegant zebrafish studies 
focused on primordial cell migration in response to SDF-1/CXCL12 gradients have implicated an 
important function for ACKR3 in this regard (23, 24). However, the molecular partners that enable 
ACKR3 to rapidly and cell autonomously scavenge ligands from the extracellular compartment 
remain unknown (25). RAMP3, by virtue of its C-terminal PSD-95/Discs-large/ZO-1 homology 
(PDZ)-recognition motif associates with N-ethylmaleimide-sensitive factor (NSF). This has 
previously been shown to facilitate the rapid recycling and resensitization of CLR to the plasma 
membrane following ligand-dependent internalization (26).  Using confocal imaging, we confirmed 
these original findings for CLR following a 4 hour recovery after removal of AM ligand (SI 
Appendix, Fig. S3 and Fig. S4). Similarly, we found that HEK293T cells transfected with ACKR3, 
RAMP3 and NSF displayed rapid internalization of ACKR3 following 1 hour of AM ligand 
stimulation, with subsequent recycling of ACKR3 to the plasma membrane after 4 hours of ligand 
removal and cycloheximide treatment (Fig. 3C, left column and SI Appendix, Fig. S5). In 
contrast, in the absence of either RAMP3 or NSF, although ACKR3 ligand-stimulated 
internalization occurred at 1 hour, the receptor failed to recycle to the plasma membrane and 
remained within intracellular vesicles after 4 hour recovery (Fig. 3C, middle and right columns 




recycling of the ACKR3 to the plasma membrane where it can evoke its ligand scavenging 
activities. 
Following this same experimental paradigm, we were curious to address whether 
RAMP3:NSF expression could influence the fate of ACKR3 to different endosomal sorting 
pathways. To address this, we tracked the ligand-activated internalization of tagged-ACKR3 to 
fluorescently-labeled, Rab-positive endosomes in the presence or absence of RAMP3:NSF. As 
shown in Fig. 4A (left columns and SI Appendix, Fig. S6), ACKR3 rapidly internalized to Rab4-
positive vesicles following 1 hour treatment of AM ligand and was subsequently recycled to the 
plasma membrane after 4 hours recovery in the presence of RAMP3:NSF. Conversely, in the 
absence of RAMP3:NSF, AM-stimulated ACKR3 internalized to non-Rab4-positive vesicles and 
never returned to the cell surface (Fig. 4A, right columns and SI Appendix, Fig. S6).  Moreover, 
when cells were transfected with a GFP-Rab7a lysosomal marker, AM-activated ACKR3 was 
spared from the lysosomal degradation pathway, and resensitized to the plasma membrane, in 
the presence of RAMP3:NSF (Fig. 4B, left columns and SI Appendix, Fig. S7). In the absence 
of RAMP3:NSF, however, ACKR3 was predominately sorted toward the lysosomal pathway, 
where its localization within the lumen of Rab7a-positive lysosomes and absence from the plasma 
membrane was particularly evident 4 hours after AM-stimulation (Fig. 4B, right columns and SI 
Appendix, Fig. S7). Importantly, we found the same effects of RAMP3:NSF on ACKR3 sorting 
when the receptor was activated by SDF-1/CXCL12 (SI Appendix, Fig. S8, Fig. S9, and Fig. 
S10), indicating a ligand-unbiased requirement of RAMP3:NSF for the sorting of ACKR3 to rapidly 
recycling Rab4-positive endosomes, while being spared from lysosomal degradation. 
It has been established that the PDZ recognition sequence in the C’ terminal tail of RAMP3 
plays a critical role in the recycling of the canonical CLR:RAMP3:NSF complex (26). To test the 
hypothesis that the RAMP3 type I PDZ recognition motif is a molecular determinate of 




of the PDZ motif (-DTLL) disrupted the ligand-stimulated, selective endosomal sorting of the 
ACKR3:RAMP3 receptor complex (SI Appendix, Fig. S11, for AM ligand and Fig. S12, for 
CXCL12 ligand) irrespective of ligand specificity. Interestingly, we also noted that the receptor 
complex instead localized to Rab11 slow recycling endosomes, which was previously not 
detected with wild-type RAMP3.  
Loss of guided cell migration in Ackr3-/- and Ramp3-/- mice during retinal angiogenesis  
 To determine whether RAMP3-mediated fating of ACKR3 to the rapid recycling endosomal 
pathway could impact the scavenging properties of the receptor in a physiological context, we 
turned to postnatal retinal angiogenesis as a model system of guided cell migration (27). In this 
context, angiogenic cues, like SDF-1/CXCL12 and AM, are enriched within peripheral astrocytes 
and serve as chemotactic gradients for guided angiogenesis of retinal vasculature by stimulating 
tip cells and filopodia ((28) and Fig. 5A,D,G). Previous studies have defined the presence of 
ACKR3 within trailing arterioles and concomitantly its notable absence from leading endothelial 
tip cells within the developing retina, thereby establishing its spatial positioning within the retina 
to maintain angiogenic gradients (28). Predictably, a 50% reduction in the expression of the 
scavenging receptor in Ackr3+/- animals resulted in a significant reduction in the number of 
endothelial tip cells within the retinas of postnatal day 3 mice compared to control littermates (Fig. 
5B,E).  Although the vast majority of Ackr3-/- mice die at postnatal day 1, we were fortunate to 
obtain and characterize a single, surviving animal which displayed a profound reduction in tip cell 
number (Fig. 5E) and effacement of the retinal angiogenic front.   Importantly, we observed the 
same attenuation of guided angiogenesis in Ramp3-/- animals (29) compared to control littermates 
(Fig. 5C,F).  Additionally, we observed a significant decrease in tip cell filopodia in Ramp3-/- 
animals (WT vs Ramp3-/-; 20.7 ± 1.34 vs 16.9 ± 0.90, p=0.023) and a trend toward decreased tip 




findings support an essential physiological function for AM-gradient guided cell migration through 
the scavenging activities of ACKR3 and RAMP3 (Fig. 5G).  
Discussion 
Collectively, these data significantly expand the repertoire of GPCRs that interact with 
RAMPs and provide at least one example of how a RAMP:GPCR interaction can dictate the 
physiological functions of guided cell migration by governing receptor endosomal sorting and 
recycling (Fig. 5H). We focused our efforts on the process of retinal angiogenesis because we, 
and others, have previously shown that both ACKR3 ligands, SDF-1/CXCL12 and AM, and their 
respective cognate signaling receptors, CXCR4 and CLR, are critical for driving guided cell 
migration within this vascular bed (28, 30). However, ACKR3 also plays critical roles in the 
migration of GABAergic interneurons within the embryonic cerebral cortex (1, 31), in the homing 
of immune cells to lymphoid tissues and in the migration of cancer cells (32, 33). Thus, it will be 
of interest to determine whether RAMP3 also dictates the scavenging functions of ACKR3 within 
these other contexts. If so, the RAMP3-ACKR3 interface should provide a novel therapeutic target 
for modulating the actions of the CXCR4/CXCL12 axis in anti-cancer and anti-inflammatory 
strategies (34). 
Indeed, the molecular interface formed between RAMP1 and CLR has recently been 
exploited in the design of the anti-CGRP migraine drug, erenumab (5, 35). In our current study, 
we find that 23 of the 24 described chemokine receptors display moderate to strong molecular 
interactions with RAMPs. These findings identify unique and pharmacologically-tractable avenues 
for the modulation of chemokine function in a wide range of physiological processes. Additional 
studies that employ a wide range of biochemical, pharmacological, and cellular assays to 
elucidate the effects that each RAMP has on the ligand binding, biased functional selectivity or 




Materials and Methods 
Cell culture, Bioluminescence Resonance Energy Transfer (BRET) assays, flow 
cytometry, immunofluorescence confocal microscopy, whole-mount immunohistochemistry, in 
situ proximity ligation assay (PLA), receptor scavenging, internalization, resensitization, and 
trafficking assays performed in this study are provided in SI Appendix, Materials and Methods. 
Animals 
Adm+/hi and Ackr3+/- mice were maintained on a C57BL/6 genetic background and Ramp3-
/- mice were maintained on a 129/SvEv genetic background. Ackr3-/- and Admhi/hi mice were 
generated by heterozygous intercrosses, respectively. Ramp3-/- mice were generated through 
homozygous crosses of Ramp3-/- mice and Ramp3+/+ isogenic mice were used as controls.  A 
total of 6 mice across two Adm genotypes (3 Adm+/+ and 3 Admhi/hi), 11 mice across the three 
Ackr3 genotypes (4 Ackr3+/+, 6 Ackr3+/-, and 1 Ackr3-/-), and 14 mice across two Ramp3 genotypes 
(7 Ramp3+/+  and 7 Ramp3-/-) were used in this study. This study was powered to attain statistical 
significance of p<0.05 with a 90% probability between Adm+/+ and Admhi/hi, Ackr3+/+ and Ackr3+/-, 
and Ramp3+/+ and Ramp3-/- mice.  All animal procedures and protocols were approved by the 
UNC-CH Institutional Animal Care and Use Committee. 
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Figure Legends 
Fig. 1. BRET screening of the chemokine receptor family reveals heterodimers with 
receptor activity modifying proteins (RAMPs).  ΔBRET was determined using HEK293T cells 
for each receptor: RAMP pair and plotted as a function of the total fluorescence/total 
luminescence ratio. Curves were calculated using one site binding (hyperbola) and representative 
saturation isotherms are displayed for each receptor. A systematic, multi-component approach 




were deemed negative (red).  Next, a comparison of fits between hyperbolic and linear models 
was used where Linear R2 > Hyperbolic R2 was deemed a poor interaction (yellow). Finally, the 
remaining interactions were deemed good or strong based on the BRET50 values, BRET50> 10 
(blue) or BRET50< 10 (green), respectively.  Curves are representative of n=3-4 independent 
experiments for each RAMP-receptor interaction, with average data reported in Supplemental 
Table 1. 
Fig. 2. Cellular distribution of ACKR3: RAMP3 and translocation to the plasma membrane. 
(A) HEK293T cells transfected with HA-RAMP alone or with Myc-CLR or Myc-ACKR3 as 
indicated. Addition of CLR and ACKR3 resulted in an increased the detection of GPCR: RAMP at 
the plasma membrane. HA-tagged RAMP2 and RAMP3 exhibited very low levels of GPCR 
independent localization. n=3 for each condition. (B) Proximity ligation assay (PLA) showed 
significant increases in signal for CLR with RAMP3 and ACKR3 with RAMP3 when compared with 
GPCR alone transfected controls. Blue is the nuclear staining and green is beta catenin to stain 
the membrane. The graph shows the number of PLA signals per cell that correspond to number 
of associations or heterodimer complexes for GPCR with RAMP3. Each color represents an 
individual experiment, n=3, counting 7-21 individual cells per n. Statistical significance was 
determined by an unpaired t test. Error bars represent SEM of the means. Scale bar 10µm. 
Fig. 3. The ACKR3: RAMP3: NSF complex attenuates adrenomedullin signaling and 
regulates the ACKR3 receptor’s rapid recycling. (A) Expression of ACKR3 in the same 
HEK293T cells as the CLR: RAMP3 heterodimer resulted in a marked decrease in cAMP EPAC 
biosensor signal, indicating reduced potency and a resulting biphasic dose-response (EC50 for –
ACKR3= 1.6 nM, ± logEC50=0.11 to +ACKR3 EC50_1= 1 nM, ± logEC50_1= 0.20 and EC50_2= 
3.1 µM, ± logEC50_2= 0.46 with Hill slope for –ACKR3= 0.58 ± 0.08 and nHill slope for +ACKR3 
nH1=-0.92 ± 0.40 and nH2=-1.17 ± 0.99) (B) Coculturing the CLR: RAMP3: EPAC reporter cells 




represented by the rightward shift in the EC50 from 0.52 nM ± logEC50=0.05 to 1.3 nM ± 
logEC50=0.08 (Hill slope for +GLP2R = 0.86 ± 0.08, Hill slope for +ACKR3 = 0.50 ± 0.05) For both 
A and B, curves and statistical significance were determined by nonlinear regression with a 
comparison of fits (F-test), n=6 in duplicate. (C) Immunofluorescence confocal microscopy shows 
ACKR3: RAMP3 colocalized at the plasma membrane. HEK293T cells were either not treated 
with ligand and fixed, treated with AM for 1 h and fixed, or treated with AM for 1 h washed/ allowed 
to recover for 4 h, and fixed. After ligand stimulation, ACKR3 and RAMP3 internalized and showed 
colocalization with NSF intracellularly. ACKR3 in the presence of RAMP3 and NSF (left column) 
resulted in the ACKR3: RAMP3 complex localizing to the plasma membrane after the four hour 
recovery phase. ACKR3 in the absence of NSF (center column) or RAMP3 (right column) did not 
recycle to the plasma membrane after removal of ligand and 4 h recovery. Images are 
representative of 3 independent experiments. Scale bar 10 µm. 
Fig. 4. RAMP3 rescues internalized ACKR3 from Rab7a-positive late endosomes, diverting 
the receptor to Rab4-positive rapid recycling vesicles resulting in resensitization after AM 
treatment. (A) HEK293T cells transfected with RFP-Rab4 and ACKR3 ±RAMP3/NSF were either 
not treated with AM, treated with 100 nM AM for 1 h and fixed, or treated and allowed to recover 
for 4 h. After 1 h AM treatment, ACKR3 +RAMP3/NSF are internalized and show colocalization 
with Rab4 intracellularly (middle row, first column and inset). In the ACKR3 –RAMP3/NSF 
condition, ACKR3 is internalized but colocalization with Rab4 does not occur (middle row, third 
column and inset). After a 4 h recovery time post-AM treatment, in the ACKR3 +RAMP3/NSF 
cells, ACKR3 and RAMP3 show distribution at the plasma membrane of the cell, demonstrating 
recycling of the receptor complex (bottom row, first column and inset). In the ACKR3 –
RAMP3/NSF cells, after the 4 h recovery, ACKR3 is not present at the plasma membrane and 
the receptor remained intracellular (bottom row, third column and inset). (B) Conversely, 




stated above. After 1 h AM treatment, ACKR3 +RAMP3/NSF are internalized and show limited/no 
colocalization with Rab7a intracellularly (middle row, first column and inset). However, in the 
ACKR3 –RAMP3/NSF condition, ACKR3 is internalized and shows robust localization in the 
lumen of Rab7a-postive vesicles (middle row, third column and inset). After a 4 h recovery time 
post-AM treatment, in the ACKR3 +RAMP3/NSF cells, ACKR3 and RAMP3 show distribution at 
the plasma membrane of the cell, demonstrating recycling of the receptor complex (bottom row, 
first column and inset). In the ACKR3 –RAMP3/NSF cells, after the 4 h recovery, ACKR3 is not 
present at the plasma membrane but is detected in the lumen of Rab7a-late endosomes (bottom 
row, third column and inset). Images are representative of three independent experiments. Scale 
bar 10 µm. 
Fig. 5. Vascular development is disrupted upon genetic deletion of ACKR3 or RAMP3 in 
vivo through a RAMP3-mediated rapid recycling mechanism. (A-C) Representative images 
of whole mount immunofluorescence staining of postnatal day 3 retinal vasculature using isolectin 
B4 in control, AM over-expressing (Admhi/hi), ACKR3 heterozygous (Ackr3+/-), ACKR3 knockout 
(Ackr3-/-), and RAMP3 knockout (Ramp3-/-) mice. Statistics were evaluated using n=3-7 mice. 
Scale Bars, 200 μM. (D-F) Analysis and quantification of the retinal tip cells detected at the 
vascular periphery in control and gene targeted mice. Colored dots represent quantitation from 
different retinal quadrants of individual animals.  Statistical significance was determined by an 
unpaired, 2-tailed t-test with an n between 3-7 mice, as indicated in the figure. Error bars represent 
SEM of the means. (G) Cartoon depicting gradient-guided migration of vascular endothelial tip 
cells in response to normal chemotactic gradients (top) established by ACKR3/RAMP3 
(yellow/green) and abnormal gradients (bottom) in the absence of ACKR3/RAMP3 ligand 
scavenging.   (J) Model of RAMP3-mediated endosomal sorting of ACKR3.  I. Ligand binding of 
ACKR3 leads to endocytosis of receptor. II. ACKR3 is internalized to early endosomes, where it 




for the Rab4-positive rapid recycling endosome-dependent and RAMP3-facilitated recycling of 
internalized ACKR3 to the cell surface via a putative interaction with a PDZ domain containing 
protein. In the absence of RAMP3, ACKR3 is localized to Rab7a-positive late endosomes which 
controls the trafficking between late endosomes and lysosomes. IV. ACKR3 scavenging is 







Supplementary Materials and Methods 
Generation of expression plasmids 
Chemokine receptor cDNA was either purchased from cDNA.org (Bloomsburg University, 
PA) or a gift from Dr. Sudar Rajagopal (ACKRs 1/2/4/5).  All receptors were ligated into a 
CD33/Myc/rLuc backbone to generate the CD33/Myc/GPCR/rLuc. RAMP-YFP expression 
plasmids were generated by cloning into the eYFP-N1expression vector. All cloning results were 
confirmed by Sanger sequencing (Eton Biosciences, San Diego, CA). 
Cell culture and transfection 
Human embryonic kidney 293T (HEK293T) cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco) supplemented with 10% (v/v) fetal bovine serum (Sigma 
Aldrich), 10 mM HEPES (Corning), 750 µL gentamicin (Gibco) at 37oC in a humidified atmosphere 
at 5% CO2. Transient transfections were performed using lipofectamine 2000 and calcium 
phosphate where indicated. 
COS-7 cells were maintained in DMEM/F12 GlutaMAX™ (Gibco) supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (Sigma Aldrich) and 1% (v/v) antibiotic antimycotic 
(Sigma Aldrich) at 37 oC in a humidified atmosphere at 5% CO2. For transient transfections, COS-
7 cells were transfected using polyethyleneimine (PEI, 25 KDa, Polyscience Inc., 1 mg/mL) using 
a 1:3 (w:v) DNA:PEI ratio. 
Bioluminescence Resonance Energy Transfer (BRET) measurements  
HEK293T cells were seeded at 65,000 cells per well. The next day, the media was 
changed to 50 µL optimem and incubated for 2 hours at 37oC. For titration experiments, constant 
concentration of GPCR-rLuc was used with increasing amount RAMP-YFP from serial dilutions. 
In brief, GPCR-rLuc and RAMP-YFP expression vectors were mixed in optimem with 
lipofectamine and incubated for 15 min. Then, the DNA/lipofectamine/optimem mixture was added 
to corresponding wells of the 96-well plate. The next day media was replaced by 90 µL phosphate-
buffer saline containing calcium and magnesium. The assay was started by adding 10 µL of cell-
permeant substrate specific for R. reniformis luciferace, coelenterazine h (Promega, Madison, 
WI). The plate was read 10 min after addition of coelenterazine h and BRET readings were 
collected using a Mithras LB940 instrument (Berthold Technologies, Bad Wildbad, Germany) with 
MicroWin 2000 software (Berthold Technologies USA, Oak Ridge, TN). The acceptor/donor ratio 
was calculated and the curve was fitted using nonlinear regression and one-site binding with 
GraphPad Prism. 
Flow cytometry 
Cos7 cells were seeded in 24 well plates and cultured for 24 hours. Cells were transfected 
using a mixture of PEI and DNA, diluted in un-supplemented DMEM/F12 GlutaMAX™ to a total 
volume of 25 L and incubated at room temperature for 10 min. For the initial screen, cells were 
transfected with a total of 0.5 g DNA (1:1 ratio of RAMP: receptor/pcDNA3.1-zeo). For RAMP 
titration experiments, a constant concentration of GPCR (0.2 g) was used with increasing 
amounts of FLAG-RAMP. Forty-eight hours later cells were trypsinised and washed with PBS 
prior to counting. 200,000 cells were washed three times in FACS buffer (PBS supplemented with 
1% BSA and 0.03% sodium azide) before re-suspending in 50 μL FACS buffer containing either 
allophycocyanin (APC)-conjugated anti-FLAG monoclonal antibody (BioLegend, diluted 1:80 in 
FACS buffer) or APC-conjugated anti-HA monoclonal antibody (Colombia Biosciences, diluted 
1:40 in FACS buffer), where appropriate and incubated for 1 hour in the dark. The cells received 
a final three washes in FACS buffer and were re-suspended in 50 μL FACS buffer. To account 
for dead cells 2.5 μL propidium iodide was added to each sample. Samples were analyzed using 
a BD Accuri C6 flow cytometer (BD Biosciences, excitation λ 633 nm and emission λ 660 nm). 
The percentage of events with APC intensity above this threshold was calculated for each test 
condition, with an increase in intensity indicating FLAG-RAMP translocation to the plasma 
membrane. For each individual experiment, data were normalized to surface expression of FLAG-
RAMP3 when cotransfected with HA-CLR or HA-RAMP3 when cotransfected with myc-CLR-GFP, 
where appropriate, as 100% and empty vector as 0%. All data was analyzed in GraphPad Prism 
8. A one-way ANOVA with Dunnett’s post-hoc test was performed to determine any significant 
differences in cell surface expression of RAMPs compared to cells transfected with RAMP alone. 
ACKR3 G protein coupling and β-arrestin recruitment assays 
To investigate Gαs coupling, HEK293T cells were seeded in 10cm2 dish and grown over 
night. The following day, cells were transfected using calcium phosphate with the specific ACKR3 
and RAMP combination and the cAMP-sensitive biosensor EPAC at 2.5 μg, 2.5 μg, 4 μg, 
respectively. The EPAC biosensor has been studied extensively and has been proven to correlate 
linearly with agonist induced cAMP levels (1). Cells were grown overnight, trypsinized, and 
seeded at 100k cells/well into poly-D-lysine coated plates in phenol-red free, serum reduced 
media (MEM + 2%FBS + 1% Penn/Strep + 1%HEPES). The following day, the media was 
aspirated and 80 μL of PBS containing calcium and magnesium was added to each well. Then, 
10μL Coelenterazine h was added to each well and incubated for 10 min in the dark. Finally, 
compound was added to the plate and read at 30 min. 
Next, for Gαi/o coupling, HEK293T cells were seeded and transfected following the 
protocol described above. After transfected cells were seeded in 96-well plates. The following day 
80 μL of PBS containing calcium and magnesium was added to each well. 10μL Coelenterazine 
h was added to each well, and incubated for 10 min in the dark. A half-log dilution series of peptide 
ligand was generated which also contains forskolin and this was added to each well, for a final 
concentration of 10 μM forskolin/well. The plate was incubated and read at 30 min. 
Finally, for β-arrestin1/2 recruitment, HEK293T cells were seeded and transfected 
following the exact same protocol for Gαs signaling, with the exception of the transfected DNA. 
For β-arrestin recruitment, ACKR3-rLuc (1 μg) and accompanying RAMP (1 μg) are transfected 
with β-arrestin-1-YFP (5 μg) or β-arrestin-2-YFP (5μg) and a GRK (4 μg). Cells were seeded into 
a 96-well plate, the next day the media was removed and 80 μL of PBS was added to each well. 
10μL Coelenterazine h was added to each well, and incubated for 10 min in the dark. Finally, 
compound was added to the plate and read at 30 min. Data was analyzed with a non-linear curve 
fit with a variable slope for either log(agonist) or log(antagonist). 
Live cell immunofluorescence confocal microscopy 
HEK293T cells were seeding in poly-D-lysine coated Mattek 35 mm dishes and 
transfected with –CLR/+RAMP1-3, +CLR/+RAMP1-3, or +ACKR3/+RAMP1-3. The next day, cells 
were washed and incubated in staining media (SM= MEM, +L-Glutamine, +1% HEPES) 
containing primary antibodies (rabbit anti-Myc at 1:500 and goat anti-HA at 1:250) on ice for 45 
min. Staining was stopped by washing the cells with cold PBS 2x and the cells were fixed with 
4% paraformaldehyde for 30 min at room temperature. Samples were blocked for 2 hours with 
4% BSA in PBS. Appropriate secondary antibodies were applied for 2 hours at room temperature 
(donkey anti-rabbit Cy2 at 1:200 and donkey anti-goat Cy3 at 1:400). MatTek plates were washed 
2x with room temperature PBS and stained for the nucleus with Hochest at 1:1000 for 10 min. 
Cells were visualized on a Zeiss 880 confocal laser scanning microscope (UNC Hooker Imaging 
Core). All images were analyzed in FIJI(2). 
In situ proximity ligation assay (PLA) 
PLA was performed using a Duolink Fluorescence kit (Sigma Aldrich) according to 
manufacturer's instructions. HEK293T cells were seeded into 35 mm MatTek plates #P35G-0-10-
C (MatTek Corporation, Ashland, MA). The following day, cells were transfected with 250 ng of 
CD33/Myc/ACKR3 and Native Signal Sequence/3xHA/RAMP or pcDNA3.1 with calcium-
phosphate transfection mixture (3). The next day, the cells were washed with 1xPBS, fixed, 
permeabilized, and incubated with primary antibodies (Rabbit anti-Myc at 1:500 and Goat anti-
HA at 1:250) followed by incubation with anti-rabbit minus and anti-goat plus PLA probes, and 
finally with ligation and amplification mixtures. PLA reactions were further stained with β-catenin-
FITC (Sigma) and Hoechst to mark the cell walls and nucleus, respectively. Images were 
observed under Zeiss 880 confocal laser scanning microscope under 63×, oil emersion objective. 
A field of confluent cells was imaged and all cells with PLA signal were selected for counting. 
Images were processed with FIJI, and red spots were counted using Blob Finder software(4). 
Scavenger assay 
HEK293T cells were transiently transfected with the EPAC sensor and either CLR: 
RAMP3: pcDNA: NSF or CLR: RAMP3: ACKR3: NSF. The following day, cells were seeding into 
96-well plates in low serum MEM. Twenty-four hours later the media was aspirated and 80 µl of 
PBS containing calcium and magnesium was added to each well followed by addition of 10 µl 
coelenterazine solution (final concentration, 5 µM). After 10-min incubation in the dark, a 10× 
concentrated solution of a half-log dilution series of AM in PBS was added to each well and read 
on a Berthold Mithras LB940 instrument and using MicroWin 2000 software (Berthold 
Technologies). 
In the second experiment, HEK293T cells were transiently transfected with the EPAC 
sensor and CLR: RAMP3: pcDNA, generating the reporter cells. HEK293T cells were transfected 
with either ACKR3: RAMP3: NSF: pcDNA or GLP2R: pcDNA: pcDNA: pcDNA. The following day, 
the cells were seeding into 96-well plates as a 50/50 mixture (50k CLR reporter cells with 50k 
ACKR3 cells or 50k CLR reporter cells with 50k GLP2R cells) in low serum MEM. Twenty-four 
hours later the media was aspirated and 80 µl of PBS containing calcium and magnesium was 
added to each well followed by addition of 10 µl of a 50 µM coelenterazine solution (final 
concentration, 5 µM). After 10-min incubation in the dark, a 10× concentrated solution of a half-
log dilution series of AM in PBS was added to each well and the plate was then read as previously 
described above. Curves and statistical significance were determined by nonlinear regression 
with a comparison of fits (F-test) in GraphPad Prism. 
Internalization, resensitization, and trafficking assays 
HEK293T cells were transfected with ACKR3 ±RAMP3 and ± NSF or CLR ±RAMP3 and 
± NSF  Twenty-four hours post-transfection cells were treated with or without 100 nM AM for 1 h 
and fixed or allowed to recover. After agonist exposure, for receptor resensitization, cells were 
washed and incubated for 4 h in complete DMEM containing 5 µg/ml cycloheximide. Cells were 
washed 3x with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. 
Samples were permeabilized with 0.1% v/v Triton X-100 in PBS for 15 min and blocked overnight 
in PBS + 4% BSA. Samples were incubated in primary antibody in blocking buffer for 2 h at room 
temperature (mouse anti-NSF at 1:250, rabbit anti-Myc at 1:500 and goat anti-HA at 1:250). 
Appropriate secondary antibodies were applied for 2 h at room temperature (donkey anti-mouse 
Cy3 at 1:300, donkey anti-goat Cy5 at 1:300, and donkey anti-rabbit Cy2 at 1:300).  
To track ACKR3 recycling in endosomal compartments, HEK293T cells were cultured on 
poly-d-lysine coated 35 mm MatTek plates and transfected with ACKR3 +RFP-Rab4 and 
±RAMP3/NSF or ACKR3 +GFP-Rab7a and ±RAMP3/NSF. For recycling experiments using the 
RAMP3ΔPDZ protein, the same dosing paradigm was followed except cells were transfect with 
ACKR3 +RFP-Rab4 and +RAMP3ΔPDZ/NSF, ACKR3 +GFP-Rab7a and +RAMP3ΔPDZ/NSF or 
ACKR3 +RFP-Rab11 and +RAMP3ΔPDZ/NSF. Cells were treated with 100 nM AM or 15 nM 
CXCL12, fixed and permeabilized. Fixed cells were incubated with primary antibody in blocking 
buffer for 2 h at room temperature (rabbit anti-Myc at 1:500 and goat anti-HA at 1:250). 
Appropriate secondary antibodies were applied for 2 h at room temperature (donkey anti-goat 
Cy5 at 1:300, and donkey anti-rabbit Cy2 or Cy3 depending on the Rab protein at 1:300). All cells 
were visualized with a Zeiss 880 confocal laser scanning microscope under 63×, oil emersion 
objective. All images were processed with FIJI.  
Retina staining and whole-mount imaging 
P3 retinas were isolated, flat-mounted, and stained with BS-I isolectin B4 FITC conjugated 
antibody (Sigma, L2895) in Immunomix blocking solution overnight at 4˚C. Whole-mount 
fluorescent-stained retina images were captured using a Leica M205FA fluorescent stereoscope 
with QImaging Micropublisher 5.0 RTV color CCD camera. Statistical significance was determined 
by an unpaired t test, with P values of less than 0.05 considered significant. 
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Biophysical journal 99(12):4037-4046. 
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methods 9(7):676-682. 
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Supplementary Table and Figures 
 
Fig. S1. Fluorescence-activated cell sorting (FACS) analysis of chemokine receptor 
dependent surface expression of RAMPs. Cos7 cells were cotransfected with GPCR and 
RAMP at a 1:1 ratio. Plasma membrane expression of RAMPs was determined for each 
GPCR:RAMP pair by flow cytometry using either an allophycocyanin (APC)-conjugated anti-
FLAG monoclonal antibody (left hand panels) or an APC-conjugated anti-HA monoclonal antibody 
(right hand panels). An increase in APC intensity, relative to RAMP expressed alone, indicated 
GPCR-dependent promotion of RAMP cell surface expression, whilst a decrease in APC intensity 
indicated GPCR-dependent attenuation of RAMP cell surface expression. Plasma membrane 
expression was normalized to RAMP3 when cotransfected with calcitonin receptor-like receptor 
(CLR) as 100 %. Calcitonin receptor (CTR) is displayed as a positive control for a receptor that 
does not require RAMPs for plasma membrane expression. (B) Cos7 cells were transfected with 
a constant amount of CCR5, CXCR2 or ACKR3 and increase amounts of FLAG-RAMPs. 
Saturation curves were calculated using one site binding (hyperbola). All values are the mean ± 
S.E.M of at least three individual experiments. Data were determined as statistically different (*, 
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001) compared to RAMP surface expression in 
the absence of receptor using a one-way ANOVA with Dunnett’s post-hoc test. 
 
 
Fig. S2. Systematic analysis of G protein coupling and beta-arrestin recruitment by ACKR3 
in the presences and absences of RAMPs with the peptide ligands SDF-1 and AM. (A) Gαs-
dependent cAMP production following transient expression of ACKR3 and RAMPs in HEK293T 
cells was determined utilizing the EPAC biosensor. Upon treatment with either SDF-1 or AM, 
there was no detectable accumulation of intracellular cAMP. (B) Gαi/o-dependent inhibition of 
cAMP production was examined through the direct activation of adenylyl cyclase by pretreating 
ACKR3/RAMP expressing HEK293T cells with forskolin. No Gαi/o activity is observed after ligand 
addition. (C) SDF-1 and AM both recruited β-arrestin1 to ACKR3 independent of RAMP 
expression, with SDF-1 exhibiting a much higher potency than AM. (D) SDF-1 and AM recruited 
β-arrestin2 to ACKR3 again independent of RAMPs. Best fit calculated by a nonlinear regression 
with four parameters and variable slope, ± S.E.M., n= 3 in duplicate. Curves and statistical 
significance were determined by nonlinear regression with a comparison of fits (F-test). 
 
 
Fig. S3. Localization of CLR, RAMP3, and NSF in HEK293T cells during recycling upon 
treatment with the peptide ligand AM. Immunofluorescence confocal microscopy shows CLR: 
RAMP3 colocalized at the plasma membrane. HEK293T cells were either not treated with ligand 
and fixed, treated with AM for 1 h and fixed, or treated with AM for 1 h washed/ allowed to recover 
for 4 h, and fixed. After ligand stimulation, CLR and RAMP3 internalized and showed 
colocalization with NSF intracellularly. Cells that were washed and allowed to recover were 
incubated in media with 5 µg/mL cycloheximide to allow receptor recycling. CLR in the presence 
of RAMP3 and NSF (left column) resulted in the CLR: RAMP3 complex localizing to the plasma 
membrane after the 4 h recovery phase. CLR in the absence of NSF (center column) or RAMP3 
(right column) did not recycle to the plasma membrane after removal of ligand and 4 h recovery. 
Images are representative of 3 independent experiments. Scale bar 10 µm.  
 
Fig. S4. Individual channels for each protein during recycling in supplemental figure S3. 
HEK293T cells are transfected with CLR ±RAMP3 and ±NSF then cultured overnight. Cells were 
either not treated with ligand and fixed, treated with AM for 1 h and fixed, or treated with AM for 1 
h washed/ allowed to recover for 4 h, and fixed. The first column represents Myc-CLR staining 
(green), the second column represents HA-RAMP3 staining (magenta), and the third column 
represents wtNSF staining (red). Treatments and transfection conditions can be found on the left 
and right of images, respectively. Images are representative of 3 independent experiments. Scale 
bar 10 µm. 
 
Fig. S5. Individual channels for each protein during recycling in figure 3C. HEK293T cells 
are transfected with ACKR3 ±RAMP3 and ±NSF then cultured overnight. Cells were either not 
treated with ligand and fixed, treated with AM for 1 h and fixed, or treated with AM for 1 h washed/ 
allowed to recover for 4 h, and fixed. The first column represents Myc-ACKR3 staining (green), 
the second column represents HA-RAMP3 staining (magenta), and the third column represents 
wtNSF staining (red). Treatments and transfection conditions can be found on the left and right of 
images, respectively. Images are representative of 3 independent experiments. Scale bar 10 µm. 
 
Fig. S6. Individual channels for each protein during ACKR3: RAMP3: Rab4 recycling 
experiments in figure 4A. HEK293T cells are transfected with ACKR3 ±RAMP3/NSF and RFP-
Rab4 then cultured overnight. Cells were either not treated with ligand and fixed, treated with AM 
for 1 h and fixed, or treated with AM for 1 h washed/ allowed to recover for 4 h, and fixed. The 
first column represents Myc-ACKR3 staining (green), the second column represents HA-RAMP3 
staining (magenta), and the third column represents RFP-Rab4 expression (red). Treatments and 
transfection conditions can be found on the left and right of images, respectively. Images are 
representative of 3 independent experiments. Scale bar 10 µm. 
 
Fig. S7. Individual channels for each protein during ACKR3: RAMP3: Rab7a recycling 
experiments in figure 4B. HEK293T cells are transfected with ACKR3 ±RAMP3/NSF and GFP-
Rab7a then cultured overnight. Cells were either not treated with ligand and fixed, treated with 
AM for 1 h and fixed, or treated with AM for 1 h washed/ allowed to recover for 4 h, and fixed. The 
first column represents Myc-ACKR3 staining (green) and the second column represents GFP-
Rab7a expression (red). Treatments and transfection conditions can be found on the left and right 
of images, respectively. Images are representative of 3 independent experiments. Scale bar 10 
µm. 
 
Fig. S8. ACKR3 binds CXCL12 leading to internalization and resensitization through Rab4 
rapid recycling vesicles when co-expressed with RAMP3, ACKR3 resensitization is lost in 
the absences of RAMP3 through Rab7a late endosomes. (A) HEK293T cells transfected with 
RFP-Rab4 and ACKR3 ±RAMP3/NSF were treated with 15 nM CXCL12 with the same method 
as figure 6. After 1 h CXCL12 treatment, ACKR3 +RAMP3/NSF are internalized and show 
colocalization with Rab4 intracellularly (middle row, first column and inset). In the ACKR3 –
RAMP3/NSF condition, ACKR3 is internalized but colocalization with Rab4 does not occur (middle 
row, third column and inset). After a 4 h recovery time post-CXCL12 treatment, in the ACKR3 
+RAMP3/NSF cells, ACKR3 and RAMP3 show distribution at the plasma membrane of the cell, 
demonstrating recycling of the receptor complex (bottom row, first column and inset). In the 
ACKR3 –RAMP3/NSF cells, after the 4 h recovery, ACKR3 is not present at the plasma 
membrane and the receptor remained intracellular (bottom row, third column and inset). (B) 
Conversely, HEK293T cells transfected with GFP-Rab7a and ACKR3 ±RAMP3/NSF were treated 
with CXCL12. After 1 h CXCL12 treatment, ACKR3 +RAMP3/NSF are internalized and show no 
colocalization with Rab7a intracellularly (middle row, first column and inset). In the ACKR3 –
RAMP3/NSF treated cells, ACKR3 is internalized and shows robust localization in the lumen of 
Rab7a-postive vesicles (middle row, third column and inset). After a 4 h recovery time post-
CXCL12 treatment, in the ACKR3 +RAMP3/NSF cells, ACKR3 and RAMP3 show distribution at 
the plasma membrane of the cell, demonstrating recycling of the receptor complex (bottom row, 
first column and inset). In the ACKR3 –RAMP3/NSF cells, after the 4 h recovery, ACKR3 is not 
present at the plasma membrane but is detected in the lumen of Rab7a-late endosomes (bottom 
row, third column and inset). Images are representative of at least two independent experiments. 
Scale bar 10 µm. 
 
Fig. S9. Individual channels for each protein during ACKR3: RAMP3: Rab4 recycling 
experiments in figure S8A. HEK293T cells are transfected with ACKR3 ±RAMP3/NSF and RFP-
Rab4 then cultured overnight. Cells were either not treated with ligand and fixed, treated with 
CXCL12 for 1 h and fixed, or treated with CXCL12 for 1 h washed/ allowed to recover for 4 h, and 
fixed. The first column represents Myc-ACKR3 staining (green), the second column represents 
HA-RAMP3 staining (magenta), and the third column represents RFP-Rab4 expression (red). 
Treatments and transfection conditions can be found on the left and right of images, respectively. 
Images are representative of at least two independent experiments. Scale bar 10 µm. 
  
 
Fig. S10. Individual channels for each protein during ACKR3: RAMP3: Rab7a recycling 
experiments in figure S8B. HEK293T cells are transfected with ACKR3 ±RAMP3/NSF and GFP-
Rab7a then cultured overnight. Cells were either not treated with ligand and fixed, treated with 
CXCL12 for 1 h and fixed, or treated with CXCL12 for 1 h washed/ allowed to recover for 4 h, and 
fixed. The first column represents Myc-ACKR3 staining (green) and the second column 
represents Rab7a expression (red). Treatments and transfection conditions can be found on the 
left and right of images, respectively. Images are representative of at least two independent 
experiments. Scale bar 10 µm. 
 
 
Fig. S11. Deletion of the RAMP3’s type I PDZ results in the dysregulation of the 
ACKR3:RAMP3 complex during AM stimulation. (A) HEK293T cells transfected with Rab4, 
Rab7, or Rab11 and ACKR3 +RAMP3ΔPDZ/NSF were not treated with AM, treated with 100 nM 
AM for 1 h and fixed, or treated and allowed to recover for 4 h. Under basal conditions, the deletion 
of the type I PDZ domain resulted in an increase in the receptor complex internalizing and 
interacting with all three Rabs, which was not previously detected with WT-RAMP3. After 1 h AM 
treatment, ACKR3 + RAMP3ΔPDZ/NSF are internalized and show colocalization with all three 
Rabs intracellularly (middle row and insets). After a 4 h recovery time post-AM treatment, in the 
ACKR3 + RAMP3ΔPDZ/NSF cells, ACKR3 and RAMP3 show distribution at the plasma 
membrane of the cell, as well as localizing to Rab4, 7, and 11 positive vesicles indicating an 
inability of the mutant RAMP3 to control the vesicular trafficking of the ACKR3: RAMP3ΔPDZ/NSF 
complex (bottom row and insets). Images are representative of three independent experiments. 











Fig. S12. Deletion of the RAMP3’s type I PDZ results in the dysregulation of the 
ACKR3:RAMP3 complex during CXCL12 stimulation. (A) HEK293T cells transfected with 
Rab4, Rab7, or Rab11 and ACKR3 +RAMP3ΔPDZ/NSF were not treated with CXCL12, treated 
with 15 nM CXCL12 for 1 h and fixed, or treated and allowed to recover for 4 h. Under basal 
conditions, the deletion of the type I PDZ domain resulted in an increase in the receptor complex 
internalizing and interacting with all three Rabs, which was not previously detected with WT-
RAMP3. After 1 h CXCL12 treatment, ACKR3 + RAMP3ΔPDZ/NSF are internalized and show 
colocalization with all three Rabs intracellularly (middle row and insets). After a 4 h recovery time 
post-AM treatment, in the ACKR3 + RAMP3ΔPDZ/NSF cells, ACKR3 and RAMP3 show 
distribution at the plasma membrane of the cell, as well as localizing to Rab4, 7, and 11 positive 
vesicles indicating an inability of the mutant RAMP3 to control the vesicular trafficking of the 
ACKR3: RAMP3ΔPDZ/NSF complex (bottom row and insets). Images are representative of three 
independent experiments. Scale bar 10 µm. 
